International consensus on clinical use of presynaptic dopaminergic positron emission tomography imaging in parkinsonism

Mei Tian; Chuantao Zuo; A Cahid Civelek; Ignasi Carrio; Yasuyoshi Watanabe; Keon Wook Kang; Koji Murakami; John O Prior; Yan Zhong; Xiaofeng Dou; Congcong Yu; Chentao Jin; Rui Zhou; Fengtao Liu; Xinyi Li; Jiaying Lu; Hong Zhang; Jian Wang; Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program

doi:10.1007/s00259-023-06403-0

International consensus on clinical use of presynaptic dopaminergic positron emission tomography imaging in parkinsonism

Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):434-442. doi: 10.1007/s00259-023-06403-0. Epub 2023 Oct 4.

Authors

Mei Tian^{1

2

3}, Chuantao Zuo^{4

5}, A Cahid Civelek⁶, Ignasi Carrio⁷, Yasuyoshi Watanabe⁸, Keon Wook Kang⁹, Koji Murakami¹⁰, John O Prior¹¹, Yan Zhong¹², Xiaofeng Dou¹², Congcong Yu¹², Chentao Jin¹², Rui Zhou¹², Fengtao Liu^{13

14}, Xinyi Li^{13

14}, Jiaying Lu^{15

13}, Hong Zhang^{16

17

18

19}, Jian Wang^{20

21}; Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program

Affiliations

¹ Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China. tianmei@fudan.edu.cn.
² Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, China. tianmei@fudan.edu.cn.
³ Human Phenome Institute, Fudan University, Shanghai, 201203, China. tianmei@fudan.edu.cn.
⁴ Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China. zuochuantao@fudan.edu.cn.
⁵ National Center for Neurological Disorders & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China. zuochuantao@fudan.edu.cn.
⁶ Department of Radiology and Radiological Science, Division of Nuclear Medicine and Molecular Imaging, Johns Hopkins Medicine, Baltimore, MD, 21287, USA. acivele1@jhmi.edu.
⁷ Research Institute and Department of Nuclear Medicine, Hospital Sant Pau, Autonomous University of Barcelona, 08025, Barcelona, Spain.
⁸ Laboratory for Pathophysiological and Health Science, RIKEN Center for Biosystems Dynamics Research, Kobe, Hyogo, 650-0047, Japan.
⁹ Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea.
¹⁰ Department of Radiology, Juntendo University Hospital, Tokyo, 113-8431, Japan.
¹¹ Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland.
¹² Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, China.
¹³ National Center for Neurological Disorders & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.
¹⁴ Department of Neurology, Huashan Hospital, Fudan University, Shanghai, 200235, China.
¹⁵ Department of Nuclear Medicine and PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China.
¹⁶ Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, China. hzhang21@zju.edu.cn.
¹⁷ Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, 310009, China. hzhang21@zju.edu.cn.
¹⁸ The College of Biomedical Engineering and Instrument Science of Zhejiang University, Hangzhou, 310007, China. hzhang21@zju.edu.cn.
¹⁹ Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, 310007, China. hzhang21@zju.edu.cn.
²⁰ National Center for Neurological Disorders & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China. wangjian_hs@fudan.edu.cn.
²¹ Department of Neurology, Huashan Hospital, Fudan University, Shanghai, 200235, China. wangjian_hs@fudan.edu.cn.

PMID: 37789188
DOI: 10.1007/s00259-023-06403-0

Abstract

Purpose: Presynaptic dopaminergic positron emission tomography (PET) imaging serves as an essential tool in diagnosing and differentiating patients with suspected parkinsonism, including idiopathic Parkinson's disease (PD) and other neurodegenerative and non-neurodegenerative diseases. The PET tracers most commonly used at the present time mainly target dopamine transporters (DAT), aromatic amino acid decarboxylase (AADC), and vesicular monoamine type 2 (VMAT2). However, established standards for the imaging procedure and interpretation of presynaptic dopaminergic PET imaging are still lacking. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform presynaptic dopaminergic PET imaging.

Method: A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for presynaptic dopaminergic PET imaging in parkinsonism, focusing on standardized recommendations, procedures, interpretation, and reporting.

Conclusion: This international consensus and practice guideline will help to promote the standardized use of presynaptic dopaminergic PET imaging in parkinsonism. It will become an international standard for this purpose in clinical practice.

Keywords: Brain imaging; Dopamine; Expert consensus; Parkinsonism; Positron emission tomography (PET).

MeSH terms

Consensus
Dopamine / metabolism
Dopamine Plasma Membrane Transport Proteins / metabolism
Humans
Parkinson Disease* / metabolism
Parkinsonian Disorders* / diagnostic imaging
Positron-Emission Tomography / methods

Substances

Dopamine
Dopamine Plasma Membrane Transport Proteins

Grants and funding

2021YFA1101700/Dream Project of Ministry of Science and Technology of the People's Republic of China